Yasuda K, Johnston J M
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas 75235-9051.
Endocrinology. 1992 Feb;130(2):708-16. doi: 10.1210/endo.130.2.1733719.
Platelet-activating factor-acetylhydrolase (PAF-AH), the enzyme that inactivates PAF, is decreased in the plasma of both rabbits and humans during the latter stages of pregnancy. The activity of the enzyme was decreased in rats by the administration of 1,3,5(10)-estratrien-17 alpha-ethynyl-3,17 beta-diol (17 alpha-ethynylestradiol) and increased by dexamethasone treatment. In the present study, we have further defined the hormonal regulation of PAF-AH levels in plasma of adult and juvenile rats. Estrone (E1), 17 beta-estradiol (E2), estriol (E3), and various progestins [4-pregnen-6 alpha-methyl-17 alpha-ol-3,20-dione (medroxyprogesterone), 4-estren-17 alpha-ethynyl-17 beta-ol-3-one (norethindrone), and 5(10)-estren-17 alpha-ethynyl-17 beta-ol-3-one (norethynodrel)] were administered to adult rats, and the plasma PAF-AH activities were assayed. E1, E2, and E3 administration to adult female rats lowered the plasma PAF-AH activity, E3 being the most effective. After administration of these estrogens the activity returned to the preinjection level within 4 days. The administration of medroxyprogesterone resulted in a 2-fold increase in plasma PAF-AH activity in adult female rats, and the activity remained elevated for up to 30 days. When adult male rats were treated with similar doses only a 20% increase was observed and the PAF-AH activity returned to control values by day 10. In contrast, norethindrone and norethynodrel administration resulted in a reduction of the enzyme activity in adult female rats. The plasma PAF-AH activity in juvenile male and female rats (3 weeks of age, 45-60 g body wt) was two times higher than that in adult rats of both sexes and spontaneously decreased up to the time of puberty. When juvenile male or female rats were injected with either 17 alpha-ethynylestradiol or medroxyprogesterone, a minimal change in PAF-AH activity was observed. In contrast, when dexamethasone was administered to juvenile male and female rats the plasma PAF-AH activity increased in a manner similar to adult animals. It is suggested that estrogens cause a decrease and medroxyprogesterone an increase in plasma PAF-AH activity. It is suggested that the different responsiveness to medroxyprogesterone between adult female and male rats and juvenile animals may depend on the concentration of the hormone receptor in the tissue responsible for the synthesis of PAF-AH. The decrease in PAF-AH activity after the administration of norethindrone and norethynodrel may be due to the known estrogenic activity of these steroids.
血小板活化因子乙酰水解酶(PAF-AH)是一种使PAF失活的酶,在妊娠后期,兔子和人类的血浆中该酶水平均会降低。给大鼠注射1,3,5(10)-雌甾三烯-17α-乙炔基-3,17β-二醇(17α-乙炔基雌二醇)会使该酶活性降低,而地塞米松治疗则会使其活性升高。在本研究中,我们进一步明确了成年和幼年大鼠血浆中PAF-AH水平的激素调节机制。给成年大鼠注射雌酮(E1)、17β-雌二醇(E2)、雌三醇(E3)以及各种孕激素[4-孕烯-6α-甲基-17α-醇-3,20-二酮(甲羟孕酮)、4-雌烯-17α-乙炔基-17β-醇-3-酮(炔诺酮)和5(10)-雌烯-17α-乙炔基-17β-醇-3-酮(炔诺孕酮)],并检测血浆PAF-AH活性。给成年雌性大鼠注射E1、E2和E3会降低血浆PAF-AH活性,其中E3最为有效。注射这些雌激素后,活性在4天内恢复到注射前水平。给成年雌性大鼠注射甲羟孕酮会使血浆PAF-AH活性增加两倍,且该活性在长达30天内保持升高。当给成年雄性大鼠注射类似剂量时,仅观察到活性增加20%,且PAF-AH活性在第10天恢复到对照值。相比之下,给成年雌性大鼠注射炔诺酮和炔诺孕酮会导致该酶活性降低。幼年雄性和雌性大鼠(3周龄,体重45 - 60克)的血浆PAF-AH活性是成年雌雄大鼠的两倍,且在青春期前会自发降低。当给幼年雄性或雌性大鼠注射17α-乙炔基雌二醇或甲羟孕酮时,观察到PAF-AH活性变化极小。相比之下,给幼年雄性和雌性大鼠注射地塞米松后,血浆PAF-AH活性的增加方式与成年动物相似。提示雌激素会导致血浆PAF-AH活性降低,而甲羟孕酮会使其升高。提示成年雌性和雄性大鼠以及幼年动物对甲羟孕酮的不同反应性可能取决于负责PAF-AH合成的组织中激素受体的浓度。注射炔诺酮和炔诺孕酮后PAF-AH活性降低可能是由于这些类固醇已知的雌激素活性。